{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:02Z","timestamp":1789450442144,"version":"build-2803163510"},"reference-count":48,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Selective\n                    <jats:italic>N<\/jats:italic>\n                    \u2010methyl\u2010D\u2010aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group trial was conducted in adults (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200959) with moderate\u2010to\u2010severe MDD and insufficient response to ongoing antidepressant monotherapy. Participants were randomized (1:1:1) to a novel NR2B NAM, BI\u00a01569912 (5\u2009mg or 20\u2009mg tablet) or placebo. The primary safety endpoint was the number and percentage of participants with drug\u2010related adverse events (AEs) from the start of treatment to Day 15. Dissociation and psychedelic symptoms were assessed by the Clinician\u2010Administered Dissociative States Scale (CADSS) and Bowdle\u2010Visual Analog Scale (B\u2010VAS), respectively. Preliminary efficacy assessments included the maximum decrease from baseline in the Montgomery\u2010\u00c5sberg Depression Rating Scale (MADRS) total score within a 7\u2010day interval (primary) and the change from baseline in MADRS total score at individual time points (exploratory). The proportion of participants with \u2265\u20091 AE was similar between BI\u00a01569912 and placebo, with no dose\u2010dependent trend. There was no increase in suicidal or dissociative symptoms and no clinically relevant sign of human abuse potential. The maximum decrease from baseline in MADRS within a 7\u2010day interval was similar across groups; however, a single BI\u00a01569912 20\u2010mg dose provided a clinically relevant 3.4\u2010 to 4.9\u2010point improvement in MADRS total score vs. placebo at Days 2, 4, and 6, meeting predefined criteria for further development. The favorable safety profile and preliminary efficacy signals support continued development of BI\u00a01569912 for adults with MDD.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70018","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:24:59Z","timestamp":1755170699000},"page":"1202-1212","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of the NMDA\u20102b\u2010Selective Negative Allosteric Modulator BI\u00a01569912: A Phase Ib Randomized Trial in Major Depressive Disorder"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of Toronto  Toronto Ontario Canada"},{"name":"Department of Pharmacology and Toxicology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-8829","authenticated-orcid":false,"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[{"name":"Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Walling","sequence":"additional","affiliation":[{"name":"CenExel CNS  Garden Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6252-9130","authenticated-orcid":false,"given":"Elan A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"CenExel Hassman Research Institute  Marlton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishuka","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Neuro\u2010Behavioral Clinical Research  Canton Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rosenbrock","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach an der Riss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schmitz","sequence":"additional","affiliation":[{"name":"mainanalytics GmbH  Sulzbach\/Taunus Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Scholz","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd D.","family":"S\u00fcssmuth","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach an der Riss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"De Crescenzo","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2022.09.001"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305772120"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22501"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0136-3"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2004.6.2\/wdrevets"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-008-0189-x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.03.013"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.1\/rduman"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-1130-x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14344.1"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.2.201"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230922"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718777392"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01114-y"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120959644"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302399"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r12889"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00846-5"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.05.116"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2014.00149"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818a6cea"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.897"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.02.949"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.02.612"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024465317902"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.032532"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1388"},{"key":"e_1_2_11_32_1","unstructured":"US FDA<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211243Orig1s000MedR.pdf> Accessed January 2025."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01614-3"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.184"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00816-x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13623"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-023-00140-x"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067606","article-title":"Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis","volume":"378","author":"Stone M.B.","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_11_39_1","first-page":"12","article-title":"Is high placebo response really a problem in depression trials? A critical re\u2010analysis of depression studies","volume":"16","author":"Whitlock M.E.","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720003633"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00456"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12040474"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05454-8"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05817-8"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10410236.2017.1322482"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00242"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S128584"},{"key":"e_1_2_11_48_1","unstructured":"World Health Organization.Depressive disorder (depression)<https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/depression> (2023). Accessed April 4 2024."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:06:12Z","timestamp":1762754772000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/cpt.70018"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70018","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"2025-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}